Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-propenamide, N-(3-((2-((3-fluoro-4-(4-methyl-1-piperazinyl)phenyl)amino)-7h-pyrrolo(2,3-d)pyrimidin-4-yl)oxy)phenyl)-
2. 2-propenamide, N-(3-((2-((3-fluoro-4-(4-methyl-1-piperazinyl)phenyl)amino)-7h-pyrrolo(2,3-d)pyrimidin-4-yl)oxy)phenyl)-, (2z)-2-butenedioate (1:1)
3. 2-propenamide, N-(3-((2-((3-fluoro-4-(4-methyl-1-piperazinyl)phenyl)amino)-7h-pyrrolo(2,3-d)pyrimidin-4-yl)oxy)phenyl)-, (2z)-2-butenedioate, Hydrate (1:1:2)
4. A-610ma
5. A610ma
6. Abivertinib Maleate
7. Abivertinib Maleate Anhydrous
8. Abivertinib Maleate Dihydrate
9. Ac-0010
10. Ac-0010 Maleate Dihydrate
11. Ac-0010ma
12. Ac0010
13. Ac0010ma
14. Acea100610
15. Avitinib
16. Avitinib Maleate
17. Ex-acea0010
18. Ex-acea0010ma
19. Exacea0010ma
20. Fujovee
21. N-(3-((2-((3-fluoro-4-(4-methyl-1-piperazinyl)phenyl)amino)-7h-pyrrolo(2,3-d)pyrimidin-4-yl)oxy)phenyl)acrylamide
22. Sti-5656
23. Sti5656
1. Avitinib
2. 1557267-42-1
3. Ac0010
4. N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7h-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide
5. Ex-acea0010
6. Abivertinib [usan]
7. Acea100610
8. Cer0opg92l
9. Ac-0010
10. A610
11. Abivertinib (usan)
12. 1557267-42-1 (free Base)
13. N-[3-[[2-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]prop-2-enamide
14. 2-propenamide, N-(3-((2-((3-fluoro-4-(4-methyl-1-piperazinyl)phenyl)amino)-7h-pyrrolo(2,3-d)pyrimidin-4-yl)oxy)phenyl)-
15. 2-propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]-
16. N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7h-pyrrolo(2,3-d)pyrimidin-4-yl)oxy)phenyl)prop-2-enamide
17. N-(3-{2-[3-fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7h-pyrrolo[2,3-d]pyrimidin-4-yloxy-phenyl)-acrylamide
18. Avitinib Free Base
19. Fujovee
20. Avitinib (ac0010)
21. Unii-cer0opg92l
22. Abivertinib [inn]
23. Avitinib (superceded Inn)
24. Avitinib [who-dd]
25. Abivertinib [who-dd]
26. Chembl4297865
27. Schembl15453394
28. Gtpl10044
29. Ex-a783
30. Bdbm294480
31. Avitinib(ac0010/ac0010ma)
32. Bcp16381
33. Us9586965, Cpd 3
34. Mfcd29089376
35. S8741
36. Zinc142081723
37. Ac 0010
38. Cs-w008904
39. Db15327
40. Ac-35320
41. Ds-19269
42. Hy-19816
43. N-(3-{2-[3-fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7h-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide
44. Cs-0016789
45. A16826
46. D11308
47. F17427
48. A927386
49. N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1- Yl)phenyl)amino)-7h-pyrrolo[2,3-d]- Pyrimidin-4-yl)oxy)phenyl)acrylamide
50. N-(3-(2-(3-fluoro-4-(4-methylpiperazin-1-yl)phenylamino)-7h-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl)acrylamide
51. N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenyl]-2-propenamide
| Molecular Weight | 487.5 g/mol |
|---|---|
| Molecular Formula | C26H26FN7O2 |
| XLogP3 | 4.2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 7 |
| Exact Mass | 487.21320126 g/mol |
| Monoisotopic Mass | 487.21320126 g/mol |
| Topological Polar Surface Area | 98.4 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 752 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Abivertinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Abivertinib, including repackagers and relabelers. The FDA regulates Abivertinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Abivertinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Abivertinib supplier is an individual or a company that provides Abivertinib active pharmaceutical ingredient (API) or Abivertinib finished formulations upon request. The Abivertinib suppliers may include Abivertinib API manufacturers, exporters, distributors and traders.
Abivertinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Abivertinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Abivertinib GMP manufacturer or Abivertinib GMP API supplier for your needs.
A Abivertinib CoA (Certificate of Analysis) is a formal document that attests to Abivertinib's compliance with Abivertinib specifications and serves as a tool for batch-level quality control.
Abivertinib CoA mostly includes findings from lab analyses of a specific batch. For each Abivertinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Abivertinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Abivertinib EP), Abivertinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Abivertinib USP).
LOOKING FOR A SUPPLIER?
